Skip to Main Content

An official website of the United States government

Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit  cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at OPM.gov.

Endogenous estradiol and inflammation biomarkers: potential interacting mechanisms of obesity-related disease.

About this Publication
Title
Endogenous estradiol and inflammation biomarkers: potential interacting mechanisms of obesity-related disease.
Pubmed ID
32100190 (View this publication on the PubMed website)
Digital Object Identifier
Publication
Cancer Causes Control. 2020 Feb 25
Authors
Eldridge RC, Wentzensen N, Pfeiffer RM, Brinton LA, Hartge P, Guillemette C, Kemp TJ, Pinto LA, Trabert B
Affiliations
  • Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA. ronald.eldridge@emory.edu.
  • Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
  • Pharmacogenetics Laboratory, Faculty of Pharmacy, Centre Hospitalier Universitaire (CHU) de Québec Research Center, Laval University, Quebec City, QC, Canada.
  • HPV Immunology Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc, Frederick, MD, USA.
Abstract

PURPOSE: Disentangling the effects of endogenous estrogens and inflammation on obesity-related diseases requires a clearer understanding of how the two biological mechanisms relate to each other.

METHODS: We studied 155 healthy postmenopausal women not taking menopausal hormone therapy enrolled in the Prostate Lung Colorectal and Ovarian (PLCO) screening cancer trial. From a baseline blood draw, we measured endogenous estradiol and 69 inflammation biomarkers: cytokines, chemokines, adipokines, angiogenic factors, growth factors, acute phase proteins, and soluble receptors. We evaluated the estradiol-inflammation relationship by assessing associations across different models (linear, ordinal logistic, and binary logistic) using a variety of estradiol classifications. We additionally investigated the estradiol-inflammation relationship stratified by baseline obesity status (BMI < 30 stratum and BMI > 30 stratum).

RESULTS: Associations of estradiol with 7 inflammation biomarkers met p < 0.05 statistical significance in linear and ordinal models: C-reactive protein (CRP), adiponectin, chemokine (C-X-C motif) ligand-6, thymus activation-regulated chemokine, eosinophil chemotactic protein, plasminogen activator inhibitor-1, and serum amyloid A. The positive association between estradiol and CRP was robust to model changes. Each standard deviation increase in endogenous estradiol doubled a woman's odds of having CRP levels higher than the study median (odds ratio 2.29; 95% confidence interval 1.28, 4.09). Estradiol was consistently inversely associated with adiponectin. Other estradiol-inflammation biomarker associations were not robust to model changes.

CONCLUSIONS: Endogenous estradiol appears to be associated with CRP and adiponectin; the evidence is limited for other inflammation biomarkers.

Related CDAS Studies
Related CDAS Projects